Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Akt inhibitor in preparation of drug for treating platelet number decrease related diseases

A technology for platelets and inhibitors, which is applied in the field of Akt inhibitors, the preparation of drugs for treating diseases related to the reduction of platelet counts, and can solve problems such as shortening the lifespan of platelets

Active Publication Date: 2018-06-22
SUZHOU UNIV
View PDF5 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Technical problem to be solved: The pathogenesis of thrombocytopenia caused by different etiologies is due to the shortened lifespan of platelets caused by apoptosis and activation, and is cleared

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Akt inhibitor in preparation of drug for treating platelet number decrease related diseases
  • Application of Akt inhibitor in preparation of drug for treating platelet number decrease related diseases
  • Application of Akt inhibitor in preparation of drug for treating platelet number decrease related diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0033] , experimental mice

[0034] Wild-type C57BL / 6 mice were purchased from Shanghai Slack Experimental Animal Co., Ltd. All experimental animal-related welfare is strictly implemented in accordance with the "Regulations on the Administration of Experimental Animals" of the People's Republic of China. Animal experiments were approved by the Medical Ethics Committee of Soochow University.

[0035] 2. Wash platelets

[0036] Healthy adult volunteers collected blood from the median vein of the elbow. Blood donors have no bad living habits such as smoking and drinking, and have not taken any drugs that affect platelet function within 2 weeks before blood donation. Female blood donors are not menstruating. All blood donors gave informed consent and signed the agreement. The experimental protocol was approved by the Ethics Committee of the First Affiliated Hospital of Soochow University and complied with the Declaration of Helsinki.

[0037] A certain amount of venous blo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of an Akt inhibitor in preparation of a drug for treating platelet number decrease related diseases. Experiments prove that Akt regulates apoptosis and activation of platelet by activating cyclic adenosine monophosphate dependent phosphodiesterase and phosphodiesterase medicated PKA (protein kinase A), the apoptotic and activated platelet exposes phosphatidylserine, so that the phosphatidylserine is swallowed by macrophages. Inhibition or gene knockout of Akt or Akt medicated platelet activation and apoptosis or blocking of phosphatidylserine ectropion can stop clearance of antibody-bound platelet. Research indicates that the Akt inhibitor can be used for an anti-platelet membrane glycoprotein Ib alpha antibody to induce the treatment process of platelet number change related diseases and inhibit decrease of the number of platelets in peripheral circulation blood, so that the Akt inhibitor has the potential of being developed into novel platelet protection drugs and novel drugs for treating thrombocytopenic diseases and has great scientific research and economic value.

Description

technical field [0001] The invention belongs to the field of platelet-related medicines, and in particular relates to the use of Akt inhibitors in the preparation of medicines for treating diseases related to platelet count reduction. Background technique [0002] Thrombocytopenia is a common clinical symptom, which can lead to serious consequences of hemorrhage and even fatal internal hemorrhage. Thrombocytopenia-related diseases include immune thrombocytopenia, infection-induced thrombocytopenia, secondary thrombocytopenia, drug-induced thrombocytopenia, thrombocytopenia deficiency, non-immune thrombocytopenia, and decreased platelet production diseases, diseases caused by increased platelet destruction, or thrombotic thrombocytopenic purpura, etc. The pathogenesis of thrombocytopenia caused by these different etiologies is due to the shortened lifespan of platelets caused by apoptosis and activation, and the platelets are eliminated. Immune Thrombocytopenia (ITP) is a c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61P7/04
CPCA61K45/00
Inventor 戴克胜
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products